Bookmark
Forward
Epoch making development of new drugs for prostate cancer].
Dept. of Strategic Investigation on Comprehensive Cancer Network, University of Tokyo, Tokyo, Japan.
Gan to kagaku ryoho. Cancer & chemotherapy 2013 JanSizes of these terms reflect their relevance to your search.
Prostate cancer responds well to androgen depletion therapy(ADT). However, when ADT was initiated on advanced prostate cancer, many become Castration-Resistant Prostate Cancer(CRPC)within a few years. Thus, development of new agents against CRPC is warranted. At the 2012 ASCO Meeting, results from two global randomized trials were given a warm reception. One trial involved abiraterone acetate and the other MDV3100.
Citation
Hideyuki Akaza. Epoch making development of new drugs for prostate cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2013 Jan;40(1):30-4
Mesh Tags
Substances
PMID: 23306917
View Full Text
